Jolly, S., Mehta, S. R., Wallentin, L., Afzal, R., Budaj, A., Fox, K. A. A., … Yusuf, S. (2007). The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL, 28, 187–187.

Jolly, S., S. R. Mehta, L. Wallentin, R. Afzal, A. Budaj, K. A. A. Fox, J. Col, H. J. Rupprecht, C. B. Granger, and S. Yusuf. “The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.” EUROPEAN HEART JOURNAL 28 (September 1, 2007): 187–187.

Jolly S, Mehta SR, Wallentin L, Afzal R, Budaj A, Fox KAA, et al. The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL. 2007 Sep 1;28:187–187.

Jolly, S., et al. “The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.” EUROPEAN HEART JOURNAL, vol. 28, OXFORD UNIV PRESS, Sept. 2007, pp. 187–187.

Jolly S, Mehta SR, Wallentin L, Afzal R, Budaj A, Fox KAA, Col J, Rupprecht HJ, Granger CB, Yusuf S. The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2007 Sep 1;28:187–187.